Radioligand Therapy (RLT) Market Size, Strategic Analysis, Growth Drivers, Industry Trends, Demand and Future Opportunities and Forecast Period
The market for radioligand therapy market is
expected to increase at a compound annual growth rate (CAGR) of 9.41% from 2024
to 2034, from its estimated valuation of USD 7.44 billion in 2023 to USD 20.01
million by 2034. Because of its targeted approach, which optimizes treatment efficacy
while minimizing side effects, its versatility in treating different types of
cancer, its promise for personalized medicine, and its increasing acceptance
supported by clinical data, radioligand therapy is important.
A combination of a ligand that selectively targets cancer
cells expressing particular biomarkers and a therapeutic radionuclide that
delivers lethal radiation directly to these cells is known as radioligand
therapy (RLT), an innovative and tailored approach to cancer treatment.
Request
For Free Sample Pages @ https://www.xresearch.biz/request-sample-pages/radioligand-therapy-rlt-market
GROWTH DRIVERS
One of the primary causes driving the market for
radioligand therapy is the rising incidence of cancers that are difficult to
treat, such as metastatic prostate cancer and neuroendocrine tumors. These
tumors are frequently ineffectively treated by traditional medicines like
chemotherapy or surgery, which leads to a high demand for novel treatment
approaches. The World Health Organization, for example, reports that 1,467,854
new cases of prostate cancer were reported in 2022.
With the creation of isotopes like actinium-225 (Ac-225)
and lutetium-177 (Lu-177), radiation can now be delivered to cancer cells more
precisely while protecting healthy organs. Additionally, Lutathera
(Lu-177-DOTATATE) has FDA approval to treat neuroendocrine tumors. These
developments not only improve treatment results but also increase the number of
tumors that RLT can be used to treat.
MARKET
SEGMENTATION:
By Isotope -
· Lutetium-177
(Lu-177)
· Radium
Ra 223 Dichloride
· Fluorine-18
· Gallium-68
· Other
Isotopes
By Targeted
Receptor -
· Prostate-Specific
Membrane Antigen (PSMA)
· Somatostatin
Receptor (SSTR)
· Epidermal
Growth Factor Receptor (EGFR)
· Other
Targeted Receptors (Gastrin-Releasing Peptide Receptor (GRPR), etc.)
By Indication -
· Prostate
Cancer
· Neuroendocrine
Tumors (NETS)
· Breast
Cancer
· Other
Indications
By End User -
· Hospitals
· Surgical
Care Centers
· Other
End Users
By Region -
· North
America
· Europe
· Asia
Pacific
· Latin
America
· Middle
East & Africa
Radioligand
Therapy Market Key Players:
· Bayer AG
· Novartis
· Debiopharm
· ITM
Isotope Technologies Munich SE
· Precirix
· IQVIA
· AstraZeneca
· AdvanCell
· Other
Key & Niche Players
For
More Information about this Report @ https://www.xresearch.biz/shop/radioligand-therapy-rlt-market
About
Us: -
xResearch is a
market research and consulting organization that uses unique data, expert
analysis, and new technologies to create trusted intelligence on industries.
Our research is focused on delivering an informed and impartial view on
essential market data of industry, and it is primarily driven by an in-depth
study covering the following parameters: Market Sizing and Forecasting, Market
Segmentation, Competitive Analysis, Strategic Assessment and Business
Modelling.
Contact:
Company Name: xResearch
Contact Person: James Lin
Email: sales@xresearch.biz
Phone: +1 718-619-8140
Websites:
https://www.xresearch.biz/
%20Market.jpg)
Comments
Post a Comment